Tags

Type your tag names separated by a space and hit enter

Metal attenuating therapies in neurodegenerative disease.
Expert Rev Neurother. 2011 Dec; 11(12):1717-45.ER

Abstract

The clinical and pathological spectrum of neurodegenerative diseases is diverse, although common to many of these disorders is the accumulation of misfolded proteins, with oxidative stress thought to be an important contributing mechanism to neuronal damage. As a corollary, transition metal ion dyshomeostasis appears to play a key pathogenic role in a number of these maladies, including the most common of neurodegenerative diseases. In this review, studies spanning a wide variety of neurodegenerative disorders are presented with their involvement of transition metals compared and contrasted, including more detailed treatise in relation to Alzheimer's disease, Parkinson's disease and prion diseases. For each of these diseases, a discussion of the evolving scientific rationale for the development of therapies aimed at ameliorating the detrimental effects of transition metal dysregulation, including results from various human trials, is then provided.

Authors+Show Affiliations

Department of Pathology, University of Melbourne, Parkville, Victoria 3010, Australia.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

22091597

Citation

Mot, Alexandra I., et al. "Metal Attenuating Therapies in Neurodegenerative Disease." Expert Review of Neurotherapeutics, vol. 11, no. 12, 2011, pp. 1717-45.
Mot AI, Wedd AG, Sinclair L, et al. Metal attenuating therapies in neurodegenerative disease. Expert Rev Neurother. 2011;11(12):1717-45.
Mot, A. I., Wedd, A. G., Sinclair, L., Brown, D. R., Collins, S. J., & Brazier, M. W. (2011). Metal attenuating therapies in neurodegenerative disease. Expert Review of Neurotherapeutics, 11(12), 1717-45. https://doi.org/10.1586/ern.11.170
Mot AI, et al. Metal Attenuating Therapies in Neurodegenerative Disease. Expert Rev Neurother. 2011;11(12):1717-45. PubMed PMID: 22091597.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Metal attenuating therapies in neurodegenerative disease. AU - Mot,Alexandra I, AU - Wedd,Anthony G, AU - Sinclair,Layla, AU - Brown,David R, AU - Collins,Steven J, AU - Brazier,Marcus W, PY - 2011/11/19/entrez PY - 2011/11/19/pubmed PY - 2012/8/31/medline SP - 1717 EP - 45 JF - Expert review of neurotherapeutics JO - Expert Rev Neurother VL - 11 IS - 12 N2 - The clinical and pathological spectrum of neurodegenerative diseases is diverse, although common to many of these disorders is the accumulation of misfolded proteins, with oxidative stress thought to be an important contributing mechanism to neuronal damage. As a corollary, transition metal ion dyshomeostasis appears to play a key pathogenic role in a number of these maladies, including the most common of neurodegenerative diseases. In this review, studies spanning a wide variety of neurodegenerative disorders are presented with their involvement of transition metals compared and contrasted, including more detailed treatise in relation to Alzheimer's disease, Parkinson's disease and prion diseases. For each of these diseases, a discussion of the evolving scientific rationale for the development of therapies aimed at ameliorating the detrimental effects of transition metal dysregulation, including results from various human trials, is then provided. SN - 1744-8360 UR - https://www.unboundmedicine.com/medline/citation/22091597/Metal_attenuating_therapies_in_neurodegenerative_disease_ L2 - http://www.tandfonline.com/doi/full/10.1586/ern.11.170 DB - PRIME DP - Unbound Medicine ER -